Several non-salt and solid thienopyridine derivatives as oral P2Y

Clopidogrel / pharmacology Cytochrome P-450 CYP2C19 Platelet Aggregation Inhibitors / pharmacology Prasugrel Hydrochloride / pharmacology Purinergic P2Y Receptor Antagonists / pharmacology Receptors, Purinergic P2Y12 Thienopyridines Thiophenes / pharmacology
Clopidogrel resistance Hygroscopicity P2Y(12) receptor inhibitors Prodrug design Stability Thienopyridine derivatives

Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
01 11 2022
Historique:
received: 12 07 2022
revised: 24 08 2022
accepted: 26 08 2022
pubmed: 5 9 2022
medline: 4 10 2022
entrez: 4 9 2022
Statut: ppublish

Résumé

A series of novel thienopyridine derivatives were designed and synthesized as P2Y

Identifiants

DOI: 10.1016/j.bmcl.2022.128969 PMID: 36058469
pubmed: 36058469
pii: S0960-894X(22)00445-0
doi: 10.1016/j.bmcl.2022.128969
pii:
doi:

Substances chimiques

Platelet Aggregation Inhibitors 0
Purinergic P2Y Receptor Antagonists 0
Receptors, Purinergic P2Y12 0
Thienopyridines 0
Thiophenes 0
Clopidogrel A74586SNO7
Cytochrome P-450 CYP2C19 EC 1.14.14.1
Prasugrel Hydrochloride G89JQ59I13

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

128969

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Lei Liu (L)

Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, 306 Huiren Road, Tianjin 300301, PR China; State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, 306 Huiren Road, Tianjin 300301, PR China.

Lingjun Li (L)

Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, 306 Huiren Road, Tianjin 300301, PR China; State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, 306 Huiren Road, Tianjin 300301, PR China.

Jing Yuan (J)

Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, 306 Huiren Road, Tianjin 300301, PR China; State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, 306 Huiren Road, Tianjin 300301, PR China.

Wei Liu (W)

Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, 306 Huiren Road, Tianjin 300301, PR China; State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, 306 Huiren Road, Tianjin 300301, PR China.

Yuquan Li (Y)

Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, 306 Huiren Road, Tianjin 300301, PR China; State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, 306 Huiren Road, Tianjin 300301, PR China.

Shijun Zhang (S)

Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, 306 Huiren Road, Tianjin 300301, PR China; State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, 306 Huiren Road, Tianjin 300301, PR China.

Changjiang Huang (C)

Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, 306 Huiren Road, Tianjin 300301, PR China; State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, 306 Huiren Road, Tianjin 300301, PR China. Electronic address: huangcj@tipr.com.cn.

Articles similaires

A retrospective analysis on optimal medical therapy for patients with symptomatic lower extremity peripheral artery disease: a French observational study.

Camille de Kermenguy, Anne Durand, Quentin Tollenaere et al.
1.00
Humans Peripheral Arterial Disease Retrospective Studies Male Female

CYP2C19 loss-of-function variants are independent risk factors for premature cerebral infarction: a hospital based retrospective study.

Yuliang Shi, Yuxian Yang, Miaoling Feng et al.
1.00
Humans Retrospective Studies Female Male Cytochrome P-450 CYP2C19

Emodin regulated lactate metabolism by inhibiting MCT1 to delay non-small cell lung cancer progression.

Fei Zhang, Tian Gu, Jin Li et al.
1.00
Monocarboxylic Acid Transporters Lung Neoplasms Emodin Humans Symporters

Thromboelastography with Platelet Mapping to Optimize Surgical Timing in Coronary Artery Bypass Grafting Patients on P2Y12 Receptor Blockers Therapy.

Pierpaolo Dambruoso, Pasquale Raimondo, Fabrizia Massaro et al.
1.00
Humans Coronary Artery Bypass Purinergic P2Y Receptor Antagonists Male Female

Classifications MeSH

questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Thiénopyridines › Ticlopidine › Clopidogrel › Several non-salt and solid thienopyridine...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Hémoprotéines › Cytochromes › Cytochrome P-450 enzyme system › Famille-2 de cytochromes P450 › Limonène hydroxylases › Cytochrome P-450 CYP2C19 › Several non-salt and solid thienopyridine...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents hématologiques › Antiagrégants plaquettaires › Several non-salt and solid thienopyridine...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Thiophènes › Chlorhydrate de prasugrel › Several non-salt and solid thienopyridine...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents purinergiques › Antagonistes purinergiques › Antagonistes des récepteurs purinergiques P2 › Antagonistes des récepteurs purinergiques P2Y › Several non-salt and solid thienopyridine...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs purinergiques › Récepteurs purinergiques P2 › Récepteurs purinergiques P2Y › Récepteurs purinergiques P2Y12 › Several non-salt and solid thienopyridine...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Thiénopyridines › Several non-salt and solid thienopyridine...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Thiophènes › Several non-salt and solid thienopyridine...